Cargando…
ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells
Mutations in the p53 tumor suppressor gene are the most prevalent genetic events in human Her2-positive breast cancer and are associated with poor prognosis and survival. Human clinical data and our in vitro and in vivo studies strongly suggest potent oncogenic cooperation between mutant p53 and Her...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351592/ https://www.ncbi.nlm.nih.gov/pubmed/27791982 http://dx.doi.org/10.18632/oncotarget.12878 |